11β-HSD1 inhibition reduces atherosclerosis in mice by altering proinflammatory gene expression in the vasculature

Physiological Genomics

Volumn 45, Issue 1, 2013, Pages 47-57

  Luo, Mingjuan J ^a   Thieringer, Rolf ^a   Springer, Martin S ^a   Wright, Samuel D ^a   Hermanowski Vosatka, Anne ^a   Plump, Andrew ^a   Balkovec, James M ^a   Cheng, Kang ^a   Ding, Gloria J ^a   Kawka, Douglas W ^a   Koo, Gloria C ^a   le Grand, Cheryl B ^a   Luo, Qi ^a   Maletic, Milana M ^a   Malkowitz, Lorraine ^a   Shah, Kashmira ^a   Singer, Irwin ^a   Waddell, Sherman T ^a   Wu, Kenneth K ^a   Yuan, Jeffrey ^a   Zhu, Jun ^a   Stepaniants, Serguei ^a   Yang, Xia ^a   Lum, Pek Yee ^a   Wang, I Ming ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

11 hydroxysteroid dehydrogenase type 1 (11 hsd1) glucocorticoid (GC); Apolipoprotein e deficient (ApoE ); Gene expression profiling; Inflammation

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E; CD68 ANTIGEN; CHOLESTEROL; L 750; LIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; LIPID BLOOD LEVEL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SMOOTH MUSCLE FIBER; TREATMENT DURATION; VASCULAR ENDOTHELIUM; VASCULARIZATION; VASCULITIS;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHOLESTEROL; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENES, MHC CLASS II; GLUCOCORTICOIDS; LASER CAPTURE MICRODISSECTION; LIPIDS; MICE; MICE, KNOCKOUT; MICROARRAY ANALYSIS; VASCULITIS;

ANIMALIA; MUS;

EID: 84872185794     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00109.2012     Document Type: Article

References (53)

1. Ayaori M, Sawada S, Yonemura A, Iwamoto N, Ogura M, Tanaka N, Nakaya K, Kusuhara M, Nakamura H, Ohsuzu F. Glucocorticoid receptor regulates ATP-binding cassette transporter-A1 expression and apolipoprotein-mediated cholesterol efflux from macrophages. Arterioscler Thromb Vasc Biol 26: 163-168, 2006.
2. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 364: 1746-1760, 2011.
3. Brem AS, Morris DJ, Gong R. Aldosterone-induced fibrosis in the kidney: questions and controversies. Am J Kidney Dis 58: 471-479, 2011.
4. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377: 68-71, 1995.
5. Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G, Mendelsohn ME, Jaffe IZ. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule- 1 expression and promote leukocyte adhesion. Circ Res 102: 1359-1367, 2008.
6. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 335: 2-13, 2011.
7. Coutinho AE, Gray M, Brownstein DG, Salter DM, Sawatzky DA, Clay S, Gilmour JS, Seckl JR, Savill JS, Chapman KE. 11betahydroxysteroid dehydrogenase type 1, but not type 2, deficiency worsens acute inflammation and experimental arthritis in mice. Endocrinology 153: 234-240, 2012.
8. Coutinho AE, Gray M, Brownstein DG, Salter DM, Sawatzky DA, Clay S, Gilmour JS, Seckl JR, Savill JS, Chapman KE. 11beta- Hydroxysteroid dehydrogenase type 1, but not type 2, deficiency worsens acute inflammation and experimental arthritis in mice. Endocrinology 153: 234-240, 2012.
9. Deuchar GA, McLean D, Hadoke PW, Brownstein DG, Webb DJ, Mullins JJ, Chapman K, Seckl JR, Kotelevtsev YV. 11beta-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in ApoE-/- mice. Endocrinology 152: 236-246, 2011.
10. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 131: 417-430, 2005.
11. Franchimont D, Kino T, Galon J, Meduri GU, Chrousos G. Glucocorticoids and inflammation revisited: the state of the art. NIH clinical staff conference. Neuroimmunomodulation 10: 247-260, 2002.
12. Frey FJ, Odermatt A, Frey BM. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Curr Opin Nephrol Hypertens 13: 451-458, 2004.
13. Funder JW. Aldosterone and mineralocorticoid receptors in the cardiovascular system. Prog Cardiovasc Dis 52: 393-400, 2010.
14. Funder JW. Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol Cell Endocrinol 217: 263-269, 2004.
15. Funder JW. RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 93: 121-125, 2005.
16. Funder JW. Why are mineralocorticoid receptors so nonselective? Curr Hypertens Rep 9: 112-116, 2007.
17. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol 27: 165-197, 2009.
18. Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, Ehrhart- Bornstein M, O'Shea JJ, Chrousos GP, Bornstein SR. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 16: 61-71, 2002.
19. Galuppo P, Bauersachs J. Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances. Eur J Clin Invest 42: 1112-1120, 2012.
20. Gilmour JS, Coutinho AE, Cailhier JF, Man TY, Clay M, Thomas G, Harris HJ, Mullins JJ, Seckl JR, Savill JS, Chapman KE. Local amplification of glucocorticoids by 11 beta-hydroxysteroid dehydrogenase type 1 promotes macrophage phagocytosis of apoptotic leukocytes. J Immunol 176: 7605-7611, 2006.
21. Harris HJ, Kotelevtsev Y, Mullins JJ, Seckl JR, Holmes MC. Intracellular regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-1 plays a key role in regulation of the hypothalamic- pituitary-adrenal axis: analysis of 11beta-HSD-1-deficient mice. Endocrinology 142: 114-120, 2001.
22. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS, Noonan H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer MS, Strack AM, Strowski M, Wu K, Wu T, Xiao J, Zhang BB, Wright SD, Thieringer R. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202: 517-527, 2005.
23. Hoppmann J, Perwitz N, Meier B, Fasshauer M, Hadaschik D, Lehnert H, Klein J. The balance between gluco- and mineralo-corticoid action critically determines inflammatory adipocyte responses. J Endocrinol 204: 153-164, 2010.
24. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 96: 643-650, 2005.
25. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109: 2213-2220, 2004.
26. Kristo C, Godang K, Ueland T, Lien E, Aukrust P, Froland SS, Bollerslev J. Raised serum levels of interleukin-8 and interleukin-18 in relation to bone metabolism in endogenous Cushing's syndrome. Eur J Endocrinol 146: 389-395, 2002.
27. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 11: 750-761, 2011.
28. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 109: 2698-2704, 2004.
29. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54: 2129-2138, 2009.
30. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 350: 256-265, 2012.
31. Odermatt A, Kratschmar DV. Tissue-specific modulation of mineralocorticoid receptor function by 11beta-hydroxysteroid dehydrogenases: an overview. Mol Cell Endocrinol 350: 168-186, 2012.
32. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54: 537-543, 2009.
33. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283: H1802-H1810, 2002.
34. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 21: 55-89, 2000.
35. Sell H, Eckel J. Monocyte chemotactic protein-1 and its role in insulin resistance. Curr Opin Lipidol 18: 258-262, 2007.
36. Seneviratne AN, Sivagurunathan B, Monaco C. Toll-like receptors and macrophage activation in atherosclerosis. Clin Chim Acta 413: 3-14, 2012.
37. Sikorski K, Czerwoniec A, Bujnicki JM, Wesoly J, Bluyssen HA. STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNgamma, TLR4 and IL-6 in vascular disease. Cytokine Growth Factor Rev 22: 211-219, 2011.
38. Stewart PM, Krozowski ZS. 11 beta-Hydroxysteroid dehydrogenase. Vitam Horm 57: 249-324, 1999.
39. Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J, Horiuchi M. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 26: 917-921, 2006.
40. Thieringer R, Le Grand CB, Carbin L, Cai TQ, Wong B, Wright SD, Hermanowski-Vosatka A. 11 Beta-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J Immunol 167: 30-35, 2001.
41. Trogan E, Fisher EA. Laser capture microdissection for analysis of macrophage gene expression from atherosclerotic lesions. Methods Mol Biol 293: 221-231, 2005.
42. Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MT, Fliers E, Gerdes VE, Buller HR, Brandjes DP. Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab 94: 2743-2750, 2009.
43. Walker BR. Cortisol- cause and cure for metabolic syndrome? Diabet Med 23: 1281-1288, 2006.
44. Wamil M, Battle JH, Turban S, Kipari T, Seguret D, de Sousa Peixoto R, Nelson YB, Nowakowska D, Ferenbach D, Ramage L, Chapman KE, Hughes J, Dunbar DR, Seckl JR, Morton NM. Novel fat depotspecific mechanisms underlie resistance to visceral obesity and inflammation in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 60: 1158-1167, 2011.
45. Wang M. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. Handbook of experimental pharmacology 127-146, 2011.
46. Wang M. The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome. Nutr Metab (Lond) 2: 3, 2005.
47. Weng L, Dai H, Zhan Y, He Y, Stepaniants SB, Bassett DE. Rosetta error model for gene expression analysis. Bioinformatics 22: 1111-1121, 2006.
48. Wilson P, Morgan J, Funder JW, Fuller PJ, Young MJ. Mediators of mineralocorticoid receptor-induced profibrotic inflammatory responses in the heart. Clin Sci (Lond) 116: 731-739, 2009.
49. Yang X, Peterson L, Thieringer R, Deignan JL, Wang X, Zhu J, Wang S, Zhong H, Stepaniants S, Beaulaurier J, Wang IM, Rosa R, Cumiskey AM, Luo JM, Luo Q, Shah K, Xiao J, Nickle D, Plump A, Schadt EE, Lusis AJ, Lum PY. Identification and validation of genes affecting aortic lesions in mice. J Clin Invest 120: 2414-2422, 2010.
50. Yeager MP, Guyre PM, Munck AU. Glucocorticoid regulation of the inflammatory response to injury. Acta Anaesthesiol Scand 48: 799-813, 2004.
51. Young MJ. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr Opin Nephrol Hypertens 17: 174-180, 2008.
52. Young MJ, Morgan J, Brolin K, Fuller PJ, Funder JW. Activation of mineralocorticoid receptors by exogenous glucocorticoids and the development of cardiovascular inflammatory responses in adrenalectomized rats. Endocrinology 151: 2622-2628, 2010.
53. Zhang TY, Daynes RA. Macrophages from 11beta-hydroxysteroid dehydrogenase type 1-deficient mice exhibit an increased sensitivity to lipopolysaccharide stimulation due to TGF-beta-mediated up-regulation of SHIP1 expression. J Immunol 179: 6325-6335, 2007.